These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30123982)
1. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy. Negosanti F; Tengattini V; Gurioli C; Neri I J Cosmet Dermatol; 2018 Oct; 17(5):762-765. PubMed ID: 30123982 [TBL] [Abstract][Full Text] [Related]
2. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Park J; Yun SK; Cho YS; Song KH; Kim HU Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865 [TBL] [Abstract][Full Text] [Related]
3. Targeted topical and combination laser surgery for the treatment of angiofibromas. Bae-Harboe YS; Geronemus RG Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238 [TBL] [Abstract][Full Text] [Related]
4. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus]. Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel. Krakowski AC; Nguyen TA Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829 [TBL] [Abstract][Full Text] [Related]
6. Laser treatment of angiofibromas in tuberous sclerosis. Pignatti M; Spaggiari A; Sala P; Loschi P; Fiumana E; Faggioli R Minerva Pediatr; 2014 Dec; 66(6):585-6. PubMed ID: 25336102 [TBL] [Abstract][Full Text] [Related]
7. The combination of photodynamic therapy and ultrapulse carbon dioxide laser for facial angiofibromas in tuberous sclerosis complex: A case report. Wang B; Yao Y; Huang X; Zhang L; Peng D; Zhang G Photodiagnosis Photodyn Ther; 2022 Mar; 37():102725. PubMed ID: 35041984 [TBL] [Abstract][Full Text] [Related]
8. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960 [TBL] [Abstract][Full Text] [Related]
9. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Foster RS; Bint LJ; Halbert AR Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333 [TBL] [Abstract][Full Text] [Related]
10. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683 [TBL] [Abstract][Full Text] [Related]
11. Co2/Erbium:YAG/Dye laser combination: an effective and successful treatment for angiofibromas in tuberous sclerosis. Fioramonti P; De Santo L; Ruggieri M; Carella S; Federico LT; Onesti MG; Scuderi N Aesthetic Plast Surg; 2014 Feb; 38(1):192-198. PubMed ID: 24337149 [TBL] [Abstract][Full Text] [Related]
12. Current options for the treatment of facial angiofibromas. Salido-Vallejo R; Garnacho-Saucedo G; Moreno-Giménez JC Actas Dermosifiliogr; 2014; 105(6):558-68. PubMed ID: 23522741 [TBL] [Abstract][Full Text] [Related]
13. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Weiss ET; Geronemus RG Lasers Surg Med; 2010 Jul; 42(5):357-60. PubMed ID: 20583249 [TBL] [Abstract][Full Text] [Related]
14. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report. Dill PE; De Bernardis G; Weber P; Lösch U Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875 [TBL] [Abstract][Full Text] [Related]
15. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. Wheless JW; Almoazen H J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945 [TBL] [Abstract][Full Text] [Related]
16. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex. Lee YI; Lee JH; Kim DY; Chung KY; Shin JU Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060 [TBL] [Abstract][Full Text] [Related]
17. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Weinberger CH; Endrizzi B; Hook KP; Lee PK Dermatol Surg; 2009 Nov; 35(11):1849-51. PubMed ID: 19682000 [No Abstract] [Full Text] [Related]
18. Treatment of nodular facial angiofibromas in tuberous sclerosis, using ultrapulse carbon dioxide laser. Biondo G; Greco S; Mavilia L; Mercuri SR Clin Exp Dermatol; 2014 Aug; 39(6):738-40. PubMed ID: 24890518 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial. Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial. Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H; JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]